Loading...
•
Dec 31, 2024
scPharmaceuticals Q4 2024 Earnings Report
scPharmaceuticals reported its Q4 2024 earnings results, showcasing significant revenue growth but continued net losses.
Key Takeaways
scPharmaceuticals reported strong growth in Q4 2024 with FUROSCIX revenue doubling year-over-year. Despite higher revenues, the company faced increased operating expenses leading to a net loss. Key milestones included FDA approval for an expanded FUROSCIX indication and continued expansion efforts in Integrated Delivery Networks.
FUROSCIX revenue reached $12,150,000 in Q4 2024, up 99% year-over-year.
Net loss widened to $18,845,000 compared to $13,812,000 in Q4 2023.
Cost of product revenues increased to $3,965,000 in Q4 2024.
Cash and cash equivalents stood at $75,655,000 as of December 31, 2024.
scPharmaceuticals
scPharmaceuticals
scPharmaceuticals Revenue by Segment
Revenue by Segment
FUROSCIX Revenue
CapyFin.com Forward Guidance
scPharmaceuticals anticipates continued growth fueled by expanded indications, Medicare Part D redesign, and commercial efforts. The upcoming launch of FUROSCIX for chronic kidney disease and advancement of the SCP-111 autoinjector are key focus areas for 2025.
Positive Outlook
- FDA approval of FUROSCIX for chronic kidney disease treatment.
- Anticipated launch of the new CKD indication in April 2025.
- Continued strong growth in integrated delivery networks.
- Significant tailwinds from expanded field sales force.
- Full-year impact expected from Medicare Part D redesign.
Challenges Ahead
- Continued net losses and high operating expenses.
- Dependence on the commercial success of FUROSCIX.
- Risks related to manufacturing and product delivery.
- Potential financial constraints and need for future funding.
- Uncertainties due to global economic factors impacting operations.